Perspective Therapeutics, Inc. (NYSE:CATX) Receives $12.56 Average PT from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has been given a consensus rating of “Buy” by the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $12.5556.

A number of brokerages have recently weighed in on CATX. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Saturday, July 12th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Thursday. B. Riley restated a “buy” rating and issued a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Friday, September 19th.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after purchasing an additional 3,529 shares during the last quarter. Taylor & Morgan Wealth Management LLC grew its holdings in Perspective Therapeutics by 4.4% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock valued at $323,000 after purchasing an additional 4,000 shares during the last quarter. Nicholson Wealth Management Group LLC grew its holdings in Perspective Therapeutics by 0.3% during the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock valued at $5,553,000 after purchasing an additional 5,000 shares during the last quarter. ProShare Advisors LLC grew its holdings in Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Perspective Therapeutics by 40.9% in the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after acquiring an additional 9,082 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 1.7%

Shares of CATX opened at $3.49 on Friday. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $13.56. The business’s 50-day moving average is $3.54 and its 200-day moving average is $3.07.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.